Explore more publications!
Healthcare Journal of Oregon
Got News to Share?

Healthcare Journal of Oregon: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Journal of Oregon.

February 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28

March 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31

April 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30

Press releases published on April 18, 2026

Vigor Boost Gummies Claims Evaluated: The ForceVital Male Enhancement Formula Under Investigation
2 hours ago

Vigor Boost Gummies Claims Evaluated: The ForceVital Male Enhancement Formula Under Investigation

Indeterminate GlobeNewswire
SlimLeaf Claims Evaluated: The FitBurn Formula Using Slim Leaf Ingredients for Weight Loss
4 hours ago

SlimLeaf Claims Evaluated: The FitBurn Formula Using Slim Leaf Ingredients for Weight Loss

Indeterminate GlobeNewswire
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
6 hours ago

Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting

Indeterminate GlobeNewswire
Theriva™ Biologics anuncia la próxima presentación de datos adicionales del ensayo clínico VIRAGE de Fase 2b del VCN-01 para el cáncer de páncreas metastásico en la Reunión Anual de la AACR de 2026
7 hours ago

Theriva™ Biologics anuncia la próxima presentación de datos adicionales del ensayo clínico VIRAGE de Fase 2b del VCN-01 para el cáncer de páncreas metastásico en la Reunión Anual de la AACR de 2026

Indeterminate GlobeNewswire
MAPS Welcomes Federal Action to Advance Science-Driven Psychedelic Research and Policy
8 hours ago

MAPS Welcomes Federal Action to Advance Science-Driven Psychedelic Research and Policy

Indeterminate GlobeNewswire
Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
14 hours ago

Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study

Indeterminate GlobeNewswire
Communiqué de presse : ESCMID : Le Nuvaxovid, vaccin contre la COVID-19 de Sanofi, a montré une meilleure tolérance que le mNEXSPIKE dans une étude comparative directe  
14 hours ago

Communiqué de presse : ESCMID : Le Nuvaxovid, vaccin contre la COVID-19 de Sanofi, a montré une meilleure tolérance que le mNEXSPIKE dans une étude comparative directe  

Indeterminate GlobeNewswire
VigoSurge Claims Evaluated: Analyzing the Ingredients' Benefits, Side Effects Risk and Customer Complaints
15 hours ago

VigoSurge Claims Evaluated: Analyzing the Ingredients' Benefits, Side Effects Risk and Customer Complaints

Indeterminate GlobeNewswire
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
Apr. 18, 2026

argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

Indeterminate GlobeNewswire
Steel Flow Pro Claims Evaluated: Analyzing the Prostate Support Ingredients, Side Effects Risk and Hidden Complaints
Apr. 18, 2026

Steel Flow Pro Claims Evaluated: Analyzing the Prostate Support Ingredients, Side Effects Risk and Hidden Complaints

Indeterminate GlobeNewswire
VidaCalm Claims Evaluated: Analyzing the Formula's Ingredients, Side Effects Risk and User Complaints
Apr. 18, 2026

VidaCalm Claims Evaluated: Analyzing the Formula's Ingredients, Side Effects Risk and User Complaints

Indeterminate GlobeNewswire

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions